Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | NOS2 | P35228 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | P2RY12 | Q9H244 | 5/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6077823 | 0.81 | SLC6A4 (0.44) | SLC6A4NOS2TRPV1GPR119PGR | |
| SCHEMBL2529368 | 0.79 | SLC6A4 (0.54) | SLC6A4NOS2KDM4ETRPV1GPR119 | |
| SCHEMBL6077819 | 0.78 | SLC6A4 (0.47) | SLC6A4NOS2KDM4ETRPV1MAPT | |
| SCHEMBL6078861 | 0.75 | SLC6A4 (0.52) | SLC6A4NOS2KDM4ETRPV1HTT | |
| SCHEMBL6082710 | 0.75 | SLC6A4 (0.46) | SLC6A4NOS2GPR119PGRAR | |
| Hydrochloric Acid SCHEMBL6079500 | 0.74 | SLC6A4 (0.53) | SLC6A4NOS2KDM4ETRPV1HTT | |
| SCHEMBL2532516 | 0.74 | SLC6A4 (0.55) | SLC6A4NOS2KDM4ETRPV1MAPT | |
| SCHEMBL2529137 | 0.73 | SLC6A4 (0.53) | SLC6A4NOS2TRPV1MAPTGPR119 | |
| SCHEMBL6078728 | 0.70 | SLC6A4 (0.45) | SLC6A4NOS2GPR119PGRAR | |
| SCHEMBL6078732 | 0.70 | SLC6A4 (0.45) | SLC6A4NOS2GPR119PGRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119109-B2 | Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | ASTRAZENECA AB (SE) | 2006-10-10 | — | — | US | disclosed |
| US-20040220234-A1 | Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | ASTRAZENECA AB (SE) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220234-A1 | Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | NOS3, NOS2, NOS1 | SLC6A4 1543/4885NOS2 2/4885KDM4E 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.